Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 InfectionsEJ Gane et al. Gastroenterology 151 (3), 448-456.e1. PMID 27240903. - Clinical TrialEight weeks of treatment with the combination of sofosbuvir, velpatasvir, and GS-9857 produced an SVR12 in most treatment-naïve or previously treated patients with HCV ge …
Feasibility of Individualized Treatment for Hepatitis C Patients in the Real WorldTM Chen et al. J Gastroenterol Hepatol 25 (1), 61-9. PMID 19780879.Individualized therapy is feasible in the real world, especially for patients with HCV-1 infection.
A Simple Rule to Personalize Standard Dual Therapy Across All Genotypes in Naive Chronic Hepatitis C Patients: The TT4 Randomized TrialS Francioso et al. Dig Liver Dis 46 (2), 164-9. PMID 24239044. - Randomized Controlled TrialIn HCV-naive patients, TT4-rule treatment yields similar SVR rates compared to SoC but with shorter treatment duration and remarkable cost reduction.
Treatment of Chronic HCV Genotype 1 CoinfectionC Boesecke et al. Curr HIV/AIDS Rep 12 (3), 326-35. PMID 26228050. - ReviewSeveral all-oral direct-acting antiviral (DAA) combination therapies including two fixed-dose combinations (FDCs) have been recently licensed for treatment of hepatitis C …
Fixed-dose Combination of Sofosbuvir and Ledipasvir for the Treatment of Chronic Hepatitis C Genotype 1R Kumari et al. Expert Opin Pharmacother 16 (5), 739-48. PMID 25676581. - ReviewThe FDC of LDV (90 mg) and SOF (400 mg) has a sustained virologic response of approximately 96% when given as a once-a-day pill for 3 months to both treatment-naive and - …